SGLT2 inhibitors as modulators of mitochondrial ion transport and ER-mitochondria cross talk in diabetic cardiomyopathy
Abstract
Diabetic cardiomyopathy (DCM) is a major complication of type 2 diabetes mellitus and a leading contributor to heart failure. A central feature of DCM is the disruption of mitochondrial bioenergetics and calcium homeostasis, processes that are tightly regulated through mitochondria-associated endoplasmic reticulum membranes (MAMs). These endoplasmic reticulum (ER)-mitochondria contact sites coordinate mitochondrial ion transport systems, including the mitochondrial calcium uniporter, Na+/Ca2+ exchanger, and potassium channels, which collectively govern mitochondrial metabolism, redox balance, and cell survival. Sodium-glucose cotransporter 2 inhibitors (SGLT2i), initially developed as glucose-lowering agents, have recently demonstrated robust cardioprotective effects independent of glycemic control. Emerging evidence suggests that these benefits are partly mediated through the regulation of mitochondrial function and ER stress signaling. In this review, we discuss how SGLT2 inhibitors-particularly empagliflozin, canagliflozin, and dapagliflozin-modulate mitochondrial ion homeostasis, mitochondrial dynamics, and mitophagy in diabetic hearts. We further highlight their potential role in stabilizing ER-mitochondria communication by attenuating unfolded protein response signaling and restoring calcium balance at MAM interfaces. Finally, we explore the emerging concept that combining SGLT2 inhibitors with exercise may synergistically improve mitochondrial quality control and…
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.